Adaltis

Executive Summary

Adaltis S.r.l. is a private Italian in-vitro diagnostics (IVD) company headquartered in Rome, founded in 1997. The company develops, manufactures, and markets diagnostic systems and reagents for detecting viral infections (e.g., hepatitis, HIV), diagnosing immune system diseases, and measuring human hormone responses. Adaltis has recently expanded into molecular diagnostics with systems and reagents for RT-PCR testing, including an extraction and purification platform. Its product portfolio includes the Personal LAB, a fully automated two-plate microELISA analyzer with IFA preparation features, and the NEXgen platform. The company operates primarily in the IVD market, serving hospitals, laboratories, and clinics globally. Despite limited public information on funding or valuation, Adaltis has a long track record and a diversified product line spanning immunoassay and molecular diagnostics, positioning it for growth in the expanding diagnostics sector.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation RT-PCR platform70% success
• TBDCE marking or FDA clearance for expanded molecular diagnostics menu60% success
• Q3 2026Strategic distribution partnership in emerging markets50% success